115 results
8-K
EX-99.2
PASG
Passage Bio Inc
11 Jan 21
Passage Bio Announces Plan to Deliver on Multiple Meaningful Catalysts in 2021
7:15am
personnel; failure to comply with legal and regulat ory requirements; risks relating to access to capital and credit markets; and the other risks … by renowned innovator James M. Wilson, MD, PhD Access to cutting - edge research and development Access to next - generation technologies BROAD AND ROBUST
8-K
EX-99.2
PASG
Passage Bio Inc
3 Mar 21
Passage Bio Reports Fourth Quarter and Full-Year 2020 Financial Results and Recent Business Highlights
7:01am
and retaining key personnel; failure to comply with legal and regulatory requirements; risks relating to access to capital and credit markets … Corporate model designed for success PENN GTP PARTNERSHIP Led by renowned innovator James M. Wilson, MD, PhD Access to cutting-edge research
8-K
EX-99.2
PASG
Passage Bio Inc
5 May 21
Passage Bio Reports First Quarter 2021 Financial Results and Recent Business Highlights
7:00am
relating to access to capital and credit markets; and the other risks and uncertainties that are described in the Risk Factors section of our most recent … Corporate model designed for success PENN GTP PARTNERSHIP Led by renowned innovator James M. Wilson, MD, PhD Access to cutting-edge research and development
DEF 14A
PASG
Passage Bio Inc
14 Apr 21
Definitive proxy
4:01pm
of the control number found on the proxy card or voting instruction form, as such number will be required in order for stockholders to gain access … to stockholders a Notice of Internet Availability of Proxy Materials (the “Notice of Internet Availability”) containing instructions on how to access our proxy
8-K
EX-10.1
PASG
Passage Bio Inc
18 Dec 20
Entry into a Material Definitive Agreement
7:00am
OR IMPROVEMENTS BY TENANT
ACCESS TO PREMISES
PARKING
PARTIAL INVALIDITY
LEASE BINDING UPON ASSIGNEES
LIMITATION OF LANDLORD'S LIABILITY
WAIVER
ASSIGNMENT … , and other tenants of the Project and their respective employees, suppliers, customers, and invitees, including, but not limited to access roadways
8-K
EX-99.2
dz9wwzraawv3
5 Aug 21
Passage Bio Reports Second Quarter 2021 Financial Results and Provides Recent Business Highlights
7:01am
8-K
EX-99.2
bjemfjifchyalq5vlde
4 Nov 21
Passage Bio Reports Third Quarter 2021 Financial Results and Provides Recent Business Highlights
8:00am
8-K
EX-99.1
v14vlh0fb
4 Oct 21
Regulation FD Disclosure
7:31am
S-1
EX-10.5
jy5mibhg
3 Feb 20
IPO registration
6:39am
DRS/A
EX-10.5
eaye779p30p2i xf1
10 Jan 20
Draft registration statement (amended)
12:00am
8-K
EX-99.1
hm3i8h17gnrr01ouoq
4 Nov 21
Passage Bio Reports Third Quarter 2021 Financial Results and Provides Recent Business Highlights
8:00am
8-K
EX-99.1
kwyh2k i9vlhe46f
11 Jan 21
Passage Bio Announces Plan to Deliver on Multiple Meaningful Catalysts in 2021
7:15am
DRS/A
EX-10.11
h6a0xoo3 5iizq
10 Jan 20
Draft registration statement (amended)
12:00am
8-K
EX-99.1
egum9v0zg
10 Nov 22
Passage Bio Reports Third Quarter 2022 Financial Results And Provides Business Updates
7:03am
8-K
EX-99.1
jq0t94hw3u1 qrj7
4 Aug 22
Passage Bio Reports Second Quarter 2022 Financial Results and Provides Recent Business Highlights
7:20am
8-K
EX-99.1
u83lq
11 Feb 22
Passage Bio Presents New Interim Clinical Data for Patients with GM1 Gangliosidosis in Imagine-1 Study at 2022 WORLDSymposium
11:00am
8-K
EX-99.1
2v0xz8 ci3d9du3o
5 May 21
Passage Bio Reports First Quarter 2021 Financial Results and Recent Business Highlights
7:00am
10-Q
EX-10.2
892qnmq0pbc9b txsf
11 May 20
Quarterly report
4:06pm